Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | USP19 | O94966 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ME2 | P23368 | 1/20 | 0.41 |
| ▸ | ME1 | P48163 | 1/20 | 0.41 |
| ▸ | ME3 | Q16798 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19403856 | 1.00 | L3MBTL1 (0.52) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL19403774 | 0.78 | CCR3 (0.52) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL4272470 | 0.77 | HRH3 (0.63) | L3MBTL1POLBHRH3HPGDME2 | |
| SCHEMBL19403746 | 0.77 | L3MBTL1 (0.48) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL26330641 | 0.77 | L3MBTL1 (0.48) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL26330833 | 0.77 | L3MBTL1 (0.48) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL19403775 | 0.77 | L3MBTL1 (0.47) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL26330782 | 0.77 | MC4R (0.50) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL19403773 | 0.77 | MC4R (0.50) | L3MBTL1CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL543190 | 0.76 | KCNH2 (0.42) | L3MBTL1HRH3DPP4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | L3MBTL1 3315/4885CACNA1A 3042/4885CACNA2D1 4666/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | L3MBTL1 3217/4885CACNA1A 3186/4885CACNA2D1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.